- Home
- SGN vs SXTP Comparison
SGN vs SXTP Comparison
Compare SGN & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- SXTP
- Stock Information
- Founded
- SGN 2019
- SXTP 2010
- Country
- SGN United States
- SXTP United States
- Employees
- SGN N/A
- SXTP N/A
- Industry
- SGN
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- SGN
- SXTP Health Care
- Exchange
- SGN Nasdaq
- SXTP Nasdaq
- Market Cap
- SGN 3.8M
- SXTP 3.4M
- IPO Year
- SGN 2023
- SXTP 2023
- Fundamental
- Price
- SGN $1.55
- SXTP $1.30
- Analyst Decision
- SGN
- SXTP Buy
- Analyst Count
- SGN 0
- SXTP 2
- Target Price
- SGN N/A
- SXTP $7.00
- AVG Volume (30 Days)
- SGN 657.8K
- SXTP 137.0K
- Earning Date
- SGN 08-12-2025
- SXTP 08-13-2025
- Dividend Yield
- SGN N/A
- SXTP N/A
- EPS Growth
- SGN N/A
- SXTP N/A
- EPS
- SGN N/A
- SXTP N/A
- Revenue
- SGN $391,126.00
- SXTP $984,494.00
- Revenue This Year
- SGN N/A
- SXTP $81.41
- Revenue Next Year
- SGN N/A
- SXTP $95.63
- P/E Ratio
- SGN N/A
- SXTP N/A
- Revenue Growth
- SGN N/A
- SXTP 128.70
- 52 Week Low
- SGN $0.44
- SXTP $1.24
- 52 Week High
- SGN $36.70
- SXTP $12.70
- Technical
- Relative Strength Index (RSI)
- SGN 51.32
- SXTP 33.69
- Support Level
- SGN $1.30
- SXTP $1.24
- Resistance Level
- SGN $1.85
- SXTP $1.40
- Average True Range (ATR)
- SGN 0.20
- SXTP 0.08
- MACD
- SGN 0.01
- SXTP 0.03
- Stochastic Oscillator
- SGN 50.82
- SXTP 30.77
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.